Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder (NCT07463703) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
United States15 participantsStarted 2026-04
Plain-language summary
This study tests a new brain stimulation treatment for post-traumatic stress disorder (PTSD), a condition that affects millions after trauma, causing symptoms like flashbacks, avoidance, mood changes, and heightened alertness.
The investigators will enroll 15 adults (ages 18-65) with PTSD. First, participants get a brain scan (fMRI) to map their unique brain connections between areas involved in fear and control-the right amygdala (fear center) and right dorsolateral prefrontal cortex (control area). Using this personalized map, the investigators will apply accelerated transcranial magnetic stimulation (TMS), a safe, non-invasive method using magnetic pulses to adjust brain activity. Treatment lasts 5 days (10 short sessions daily, totaling 90,000 pulses) targeting the identified spot to strengthen control over fear responses.
The study checks if this approach is practical, safe (tracking side effects like headaches), and shows early signs of reducing PTSD symptoms (measured by questionnaires and interviews). Follow-up lasts 3 months, with repeat scans to see brain changes.
This study will see if personalized, fast-paced TMS targeting the disrupted fear-control brain circuit in PTSD can be feasible and safe, and preliminarily reduce symptoms by improving brain connectivity, potentially offering a quicker alternative to standard treatments.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-65 years (inclusive)
✓. DSM-5 diagnosis of PTSD confirmed by Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
✓. PCL-5 total score ≥33 (indicating at least moderate symptom severity)
✓. PTSD symptom duration ≥3 months
✓. If taking psychotropic medications, stable dose for ≥6 weeks prior to enrollment with no planned changes during study participation
✓. Able to provide written informed consent
✓. English-speaking (required for validated assessment measures)
✓. Able to attend daily treatment sessions for 5 consecutive weekdays
Exclusion criteria
✕. Conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the head or within 30 cm of the TMS coil (excluding the mouth), including: